TELA Bio appoints Jeffrey Blizard to Board; stockholders re-elect directors

TELA Bio, Inc.

Jeffrey Blizard, Global Head of Surgical Sales at Abiomed (J&J MedTech), appointed to Board as Class III director, term to 2025 annual meeting.
Initial equity grant: option for 9,300 shares vesting monthly over 36 months and RSU for 6,375 shares vesting in three annual installments.
Annual retainer: $45,000 for Board service plus $5,000 for Nominating Committee.
Stockholders elected Kurt Azarbarzin (17,037,112 for) and Antony Koblish (18,742,180 for) as Class II directors; KPMG ratified as auditor for FY2024.

item 5.02 item 5.07 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jeffrey Blizard

member of the Board of Directors

TELA · TELA Bio, Inc.

Effective: 2024-06-04
Filed: June 6, 2024, 7:59 PM ET

On June 4, 2024, TELA Bio, Inc. (the “ Company ”) appointed Jeffrey Blizard as a member of the Company’s Board of Directors (the “ Board ”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeffrey Blizard was appointed as member of the Board of Directors at TELA Bio, Inc..

Action: appointed
Role: member of the Board of Directors

Exact text from the filing

On June 4, 2024, TELA Bio, Inc. (the “ Company ”) appointed Jeffrey Blizard as a member of the Company’s Board of Directors (the “ Board ”).

View on SEC.gov

TELA Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-069099

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.